ASH 2022 | Preliminary safety and efficacy of enitociclib in patients with NHL & CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, gives an overview of the findings of two Phase I studies assessing enitociclib in patients with non-Hodgkin lymphoma (NHL; NCT02635672) and chronic lymphocytic leukemia (CLL; NCT04978779). The study reported evidence of preliminary efficacy as well as a manageable safety profile, with no occurrences of tumor lysis syndrome (TLS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Innate Pharma: Consultancy; Pharmacyclics: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy, Other: Travel Funding; Novartis: Research Funding; Janssen: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding.
